<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03688659</url>
  </required_header>
  <id_info>
    <org_study_id>vgie</org_study_id>
    <nct_id>NCT03688659</nct_id>
  </id_info>
  <brief_title>Vancomycin, Gentamycin in Infective Endocarditis</brief_title>
  <official_title>Treatment of Infective Endocarditis by Vancomycin and Gentamycin in Assiut University Children Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infective endocarditis is a microbial infection of the endocardial surface of the heart.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infective endocarditis is usually suspected in a patient with fever and a new or changing&#xD;
      cardiac murmur and is diagnosed based on the presence of a vegetation on echocardiography and&#xD;
      positive blood cultures. Diagnosis of endocarditis is usually easy in febrile patients with a&#xD;
      continuous bacteremia and the presence of vegetation on echocardiography Infective&#xD;
      endocarditis includes bacterial endocarditis ( streptococcus viridans, enterococci and&#xD;
      staphylococcus aureus are the main causes), as well as non bacterial endocarditis as those&#xD;
      caused by viruses, fungi, chlamydia and rickettsia. It is usually superimposed on underlying&#xD;
      congenital or rheumatic cardiac lesions, it also could occur in patients who had central&#xD;
      vwnous catheter without underlying cardiac abnormality.&#xD;
&#xD;
      Infective endocarditis has been clinically divided into acute and subacute presentation.&#xD;
      Acute bacterial endocarditis is a fulminant illness over days to weeks (&lt;2 weeks), and is&#xD;
      more likely due to Staphylococcus aureus which has much greater virulence. Subacute bacterial&#xD;
      endocarditis is often due to Streptococci of low virulence and mild to moderate illness which&#xD;
      progresses slowly over weeks and months (&gt;2 weeks).&#xD;
&#xD;
      Bacterial endocarditis is a disease in which complete eradication of the organism is&#xD;
      required. Bacteria involved in endocarditis are relatively protected from phagocytic activity&#xD;
      by the vegetation, which contains high concentrations of bacteria with relatively low&#xD;
      metabolic rates. Prolonged parenteral therapy is the only way to achieve bactericidal serum&#xD;
      levels for the time needed to kill all the bacteria present in a vegetation of endocarditis.&#xD;
      Treatment generally ranges from 4-8 weeks.&#xD;
&#xD;
      Patient with native valve endocarditis caused by S.Pneumoniae may be given penicillin with or&#xD;
      without aminoglycosides.&#xD;
&#xD;
      combining an antistaphylococcal penicillin with an aminoglycoside covers against&#xD;
      S.viridan,S.aureus and grame_negative organisms.&#xD;
&#xD;
      vancomycin can be substituted for a semisynthetic penicillin if methecillin_resistant&#xD;
      staphylococcus aureus infection or penicillin allergy is suspected vancomycin plus gentamycin&#xD;
      for 4 weeks is recommended for those who are unable to tolerate B-lactam antibiotic&#xD;
      agents,and is associated with faster clearing of bactereamia Investigation; positive blood&#xD;
      culture leucocytosis elevated acute phase reactants like CRP, ESR anemia in long standing&#xD;
      cases echocardiography Treatment hospitalization and bed rest treatment of heart failure&#xD;
      using of anti coagulant therapy. antimicrobial agents:&#xD;
&#xD;
        -  several general principles provide a basis for the treatment&#xD;
&#xD;
        -  the choice of antimicrobial therapy depends on the organism and its sensetivity pattern&#xD;
&#xD;
        -  parenteral therapy specially in infants and childern&#xD;
&#xD;
        -  prolonged course usually 4-6weeks&#xD;
&#xD;
        -  bactericidal agents&#xD;
&#xD;
        -  synergetic combination: the usual initial regimens an antistaphlococcal semisynthetic&#xD;
           penicillin and an aminoglycoside(Gentamycin),if a methicillin resistant S.aureus is&#xD;
           suspected ,vancomycin should be substituted for the semisynthetic penicillin.&#xD;
&#xD;
      vancomycin should be used in place of penicillin or semisynthetic penicillin in penicillin&#xD;
      allergic patients vancomycin should be used in cases with echocardiographic signs of&#xD;
      infective endocarditis in addition to gentamycin Surgical intervention; surgical debridment&#xD;
      of infected material and replacement of the valve with a mechanical or bioprosthetic&#xD;
      artificial heart valve is necessary in certain situations.&#xD;
&#xD;
        -  patients with significant valve stenosis or regurgitation causing heart failure.&#xD;
&#xD;
        -  recurrent septic emboli despite appropriate antibiotic treatment&#xD;
&#xD;
        -  large vegetation (&gt; 10 mm)&#xD;
&#xD;
        -  abscess formation&#xD;
&#xD;
        -  early closure of mitral valve&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">January 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>vancomycin and gentamycin in infective endocarditis</measure>
    <time_frame>2 weeks</time_frame>
    <description>using combination of intravenous vancomycin and intravenous gentamycin then assessment of patients by&#xD;
1. echocardiography to detect size of intracardiac vegetation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>vancomycin and gentamycin in infective endocarditis</measure>
    <time_frame>1 weeks</time_frame>
    <description>using combination of intravenous vancomycin and intravenous gentamycin then assessment of patients by compelete blood picture to detect leucocytosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vancomycin and gentamycin in infective endocarditis</measure>
    <time_frame>4 weeks</time_frame>
    <description>using combination of intravenous vancomycin and intravenous gentamycin then assessment of patients by CRP if &gt;6 means positive results</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Infective Endocarditis</condition>
  <arm_group>
    <arm_group_label>vancomycin,gentamycin in endocarditis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with infective endocarditis will recieve intravenous infusion Vancomycin 30 mg/kg/day for 4:6 weeks and intravenous Gentamycin 3mg/kg/day for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin and gentamycin</intervention_name>
    <description>intravenous</description>
    <arm_group_label>vancomycin,gentamycin in endocarditis</arm_group_label>
    <other_name>vancomycin and geramycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients with cardiac proplem having infective endocaditis.&#xD;
&#xD;
          2. patients are newly diagnosed as recent intracardiac vegetations .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1.patients are old diagnosed as intracardiac vegetations more than 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fardous Hanem Abdelaal, professor</last_name>
    <phone>01003961323</phone>
    <email>fardousabdelhafez@med.au.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>duaa mohamed raafat, assisstant professor</last_name>
    <phone>01223112124</phone>
    <email>doaaahmed3@med.au.edu.eg</email>
  </overall_contact_backup>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>September 26, 2018</last_update_submitted>
  <last_update_submitted_qc>September 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Sarah Sobhy Habib</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis, Bacterial</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

